Dr. Haifeng Chen obtained his PhD from the University of Saarland, Germany in 1992 and awarded the Marion-Merrell-Dow Post-Doctoral Fellowship to work on a project related to adenovirus replication at the University of Kansas Medical Center in Kansas City, Kansas. From 1996 to 2006 he worked in several gene therapy companies including Cell Genesys, Genovo, Avigen, and Asklepois Biopharmaceuticals and obtained rich experiences in the gene therapy field. Afterwards he co-founded Virovek and invented several novel technologies for large-scale AAV vector manufacturing including vectors carrying toxin genes and modified capsids specifically targeting T-cells, B-cells, and certain types of solid tumor cells. Under his leadership, Virovek has now developed the capacity to provide purified AAV vectors exceeding 1 x 1017vg scale per production run. Dr. Chen served as a committee member of the Viral Gene Transfer Vector Committee of American Society of Gene and Cell Therapy (ASGCT).